Investigator Perspectives

Panelists discuss how advances in combination immunotherapy and biomarker-driven strategies are redefining frontline management of advanced melanoma, improving durability of response and paving the way for more personalized treatment approaches.

An expert discusses advances in frontline treatment for patients with EGFR-mutated non–small cell lung cancer, reviewing current standards, key clinical trials, and future directions in the evolving therapeutic landscape.

A panelist discusses recent updates in the first-line treatment of metastatic triple-negative breast cancer, including new clinical trial data, emerging therapies, and the role of biomarker-guided selection in community oncology practice.

Alicia Morgans, MD, MPH, discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved radiographic progression-free survival and overall survival compared to enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had bone metastases and limited prior treatment exposure, establishing this combination as a new standard of care when used with mandatory bone protective agents.

Panelists highlight how novel oral selective estrogen-receptor degraders SERDs and targeted therapies—guided by biomarker-driven, dynamic molecular monitoring—are transforming personalized treatment of ER-positive, HER2-negative metastatic breast cancer by improving efficacy, tolerability, and sequencing strategies to overcome resistance and enhance patient outcomes.

An expert discusses recent updates in the evolving treatment landscape of metastatic castration-resistant prostate cancer (mCRPC), highlighting new clinical trial data, emerging combination therapies, and evolving treatment selection strategies—emphasizing their implications for community oncologists aiming to balance efficacy, tolerability, and personalized care in clinical practice.

A panelist discusses how chronic graft-versus-host disease (cGVHD) affects 30-50% of allogenic transplant patients, explaining its clinical diagnosis across eight cardinal organs (particularly skin, joints, mouth and lungs), treatment approaches with corticosteroids as first-line therapy, and comparing four FDA-approved second-line agents (Ibrutinib, Belimacidil, Ruxolitinib, and Exitelimab) with their unique mechanisms of action, efficacy, and appropriate sequencing based on organ involvement.

Amandeep Salhotra, MD, discusses how chronic graft-vs-host disease (cGVHD) commonly affects transplant recipients, with risk factors including HLA mismatch and peripheral blood stem cell grafts, and how new treatments like axatilimab target the monocyte-macrophage pathway to effectively treat this condition, particularly in patients with lung involvement, while ongoing clinical trials explore both improved prophylactic strategies and corticosteroid-free interventions for moderate to severe cGVHD.

Thorvardur R. Halfdanarson, MD, discusses how neuroendocrine tumors are classified according to World Health Organization guidelines, diagnosed primarily through imaging, and treated with approaches including observation, surgery, somatostatin analogues, chemotherapy, peptide receptor radionuclide therapy, and the newly approved cabozantinib, with treatment decisions based on tumor grade, disease extent, and symptom presence.

An expert discusses recent insights from the COCOON trial, a study evaluating enhanced vs standard dermatologic management with amivantamab + lazertinib in advanced NSCLC.

Matthew Galsky, MD, discusses how recent updates in adjuvant immune checkpoint inhibition for bladder cancer emphasize the integration of agents like pembrolizumab and atezolizumab, showing improved disease-free survival post cystectomy. Ongoing trials aim to refine treatment regimens and patient selection.

Juan Pablo Alderuccio, MD, explores the evolving treatment landscape of relapsed/refractory follicular lymphoma, highlighting how novel combinations like loncastuximab tesirine plus rituximab address key therapeutic challenges through complementary targeting of CD19 and CD20, with initial evidence supporting this approach in the pursuit of improved patient outcomes.

Thomas W. LeBlanc, MD, MA, discusses how recent updates from the COMMANDS trial and advancements in anemia management, including the role of luspatercept, are shaping the treatment landscape for low-risk myelodysplastic syndromes (LR-MDS) and improving patient outcomes and quality of life.

James J. Harding, MD, discusses how emerging front-line immunotherapies, particularly the combination of nivolumab and ipilimumab, are shaping the treatment landscape for unresectable hepatocellular carcinoma (uHCC), with a focus on efficacy, safety, and patient selection.

Hope S. Rugo, MD, FASCO, provides comprehensive guidance on elacestrant’s clinical efficacy in ER+/HER2– metastatic breast cancer, including its performance in the EMERALD trial, ongoing combination studies (ELEVATE and ELECTRA), and the critical role of molecular testing and ctDNA analysis in treatment planning, while noting these data from SABCS 2024.

Hatim Husain, MD, discusses how recent updates on acquired resistance mechanisms and overall survival data for combination therapies involving amivantamab, lazertinib, and chemotherapy in EGFR-mutated NSCLC patients progressing after first-line osimertinib treatment are shaping the evolving treatment landscape and influencing clinical decision-making.

Saeed Sadeghi, MD, discusses a case of lower-risk myelodysplastic syndromes (LR-MDS), focusing on the mechanisms of action for luspatercept vs epoetin alfa, insights from the COMMANDS study, real-world data on treatment outcomes, health care resource utilization, and future directions in anemia management within this patient population.

Yoshiaki Nakamura, MD, PhD, discusses how a methylation-based circulating tumor DNA assay can enhance minimal residual disease detection and improve prognosis in patients with previously treated stage II-III colorectal cancer.

Rana McKay, MD, discusses how the first-line treatment landscape for metastatic renal cell carcinoma has evolved, comparing efficacy and safety profiles of various treatment combinations, considering patient-specific factors and disease characteristics in treatment selection, addressing the management of adverse events, and exploring ongoing challenges and future directions in therapy.

Following EHA 2024, Mazyar Shadman, MD, MPH, discusses recent updates in the evolving treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Guillermo Garcia-Manero, MD, discusses recent updates surrounding the role of erythroid maturation agents for treating anemia in patients with lower-risk myelodysplastic syndromes.

Martin H. Voss, MD, discusses recent advances in the treatment of advanced non–clear cell renal cell carcinoma and their impact on clinical practice.

Dr Dhakal provided an overview of the clinical hallmarks and risk stratification for R/R MM, as well as the current standard of care treatment options. He explored the role of CAR T-cell therapy in this setting, including an overview of the CAR-T process and criteria for identifying suitable patients.

Expert Dr. Elizabeth Plimack discusses the evolving treatment landscape of non-clear cell RCC.

Gary J. Schiller, MD, a hematologist/oncologist from UCLA Health Jonsson Comprehensive Cancer Center, provides expert perspectives on recent data updates presented at the 2023 ASH Annual Meeting.

Guillermo Garcia-Manero, MD, discusses recent advances presented at ASH 2023 in the treatment of myelodysplastic syndrome, highlighting both safety and efficacy of regimens in the frontline and second line setting.

Expert oncologists discuss the evolving treatment landscape in ER+/HER2- Metastatic Breast Cancer.

Siamak Daneshmand, MD, provides an overview of BCG-unresponsive non-muscle invasive bladder cancer and the currently available treatment options; Dr Daneshmand explains that new intravesical therapies like the TAR-200 device show promise but still require vigilant monitoring to avoid delaying cystectomy, which remains the best chance for long-term management.